# Parabilis Medicines, Inc.: financial statements, quarterly

PBLS · Nasdaq · CIK 1657677 · [Healthcare](/sectors/healthcare.md) · fiscal year ends Dec 31

Pages: [Overview](/companies/pbls.md) · [Financials](/companies/pbls/financials.md) · [Filings](/companies/pbls/filings.md) · [Insiders](/companies/pbls/insiders.md)

Standardized line items from XBRL company facts. Each value links to its filing; d marks a value derived from year-to-date figures. Other view: [annual](/companies/pbls/financials.md?period=annual).

## Income statement

| Line item | Unit | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: |
| Revenue | $m | not reported | [0.0](/filings/0001193125-26-349168.md) | not reported | [0.1](/filings/0001193125-26-349168.md) |
| Research and development | $m | not reported | [30.1](/filings/0001193125-26-349168.md) | not reported | [39.4](/filings/0001193125-26-349168.md) |
| Operating income | $m | not reported | [(36.5)](/filings/0001193125-26-349168.md) | not reported | [(50.9)](/filings/0001193125-26-349168.md) |
| Interest expense | $m | not reported | [0.4](/filings/0001193125-26-349168.md) | not reported | [0.2](/filings/0001193125-26-349168.md) |
| Net income | $m | [(38.3)](/filings/0001193125-26-349168.md) | [(34.8)](/filings/0001193125-26-349168.md) | [(45.3)](/filings/0001193125-26-349168.md) | [(52.5)](/filings/0001193125-26-349168.md) |
| Diluted EPS | $ per share | not reported | [(22.28)](/filings/0001193125-26-349168.md) | not reported | [(2.32)](/filings/0001193125-26-349168.md) |
| Basic EPS | $ per share | not reported | [(22.28)](/filings/0001193125-26-349168.md) | not reported | [(2.32)](/filings/0001193125-26-349168.md) |

- Revenue: us-gaap:Revenues
- Research and development: us-gaap:ResearchAndDevelopmentExpense
- Operating income: us-gaap:OperatingIncomeLoss
- Interest expense: us-gaap:InterestExpenseNonoperating
- Net income: us-gaap:NetIncomeLoss
- Diluted EPS: us-gaap:EarningsPerShareDiluted
- Basic EPS: us-gaap:EarningsPerShareBasic

## Balance sheet

| Line item | Unit | period not labelled (2024-12-31) | period not labelled (2025-03-31) | period not labelled (2025-06-30) | period not labelled (2025-12-31) | period not labelled (2026-03-31) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: | ---: | ---: | ---: | ---: |
| Cash and equivalents | $m | not reported | not reported | [80.4](/filings/0001193125-26-349168.md) | [27.7](/filings/0001193125-26-349168.md) | not reported | [1,087](/filings/0001193125-26-349168.md) |
| Current assets | $m | not reported | not reported | not reported | [29.4](/filings/0001193125-26-349168.md) | not reported | [1,125](/filings/0001193125-26-349168.md) |
| Total assets | $m | not reported | not reported | not reported | [80.8](/filings/0001193125-26-349168.md) | not reported | [1,175](/filings/0001193125-26-349168.md) |
| Current liabilities | $m | not reported | not reported | not reported | [56.8](/filings/0001193125-26-349168.md) | not reported | [62.8](/filings/0001193125-26-349168.md) |
| Total liabilities | $m | not reported | not reported | not reported | [97.3](/filings/0001193125-26-349168.md) | not reported | [128](/filings/0001193125-26-349168.md) |
| Long-term debt | $m | not reported | not reported | not reported | [0.6](/filings/0001193125-26-349168.md) | not reported | [0.7](/filings/0001193125-26-349168.md) |
| Current portion of debt | $m | not reported | not reported | not reported | [13.1](/filings/0001193125-26-349168.md) | not reported | [5.7](/filings/0001193125-26-349168.md) |
| Short-term borrowings | $m | not reported | not reported | not reported | [12.5](/filings/0001193125-26-349168.md) | not reported | [5.0](/filings/0001193125-26-349168.md) |
| Shareholders' equity | $m | [(384)](/filings/0001193125-26-349168.md) | [(421)](/filings/0001193125-26-349168.md) | [(455)](/filings/0001193125-26-349168.md) | [(526)](/filings/0001193125-26-349168.md) | [(570)](/filings/0001193125-26-349168.md) | [1,048](/filings/0001193125-26-349168.md) |

- Cash and equivalents: us-gaap:CashAndCashEquivalentsAtCarryingValue
- Current assets: us-gaap:AssetsCurrent
- Total assets: us-gaap:Assets
- Current liabilities: us-gaap:LiabilitiesCurrent
- Total liabilities: us-gaap:Liabilities
- Long-term debt: us-gaap:LongTermDebtNoncurrent
- Current portion of debt: us-gaap:LongTermDebtCurrent
- Short-term borrowings: us-gaap:ShortTermBorrowings
- Shareholders' equity: us-gaap:StockholdersEquity

## Shares

| Line item | Unit | period not labelled (2025-06-30) | Q2 FY2026 (2026-06-30) |
| --- | --- | ---: | ---: |
| Diluted shares (weighted) | millions of shares | [2.0](/filings/0001193125-26-349168.md) | [28.9](/filings/0001193125-26-349168.md) |

- Diluted shares (weighted): us-gaap:WeightedAverageNumberOfDilutedSharesOutstanding

Source: SEC EDGAR, XBRL company facts. Last ingested by Listed: Oct 24, 2026, 15:51 ET. No prices; not investment advice.